Archive for the ‘Scientist: Career considerations’ Category

Employment Trends in Biomedical – NIH Visualization Tool of Job Segmentation for Life Scientists


Reporter: Aviva Lev-Ari, PhD, RN

Led by Tammy Collins, Ph.D., director of the NIEHS Office of Fellows’ Career Development, team members collected detailed career outcomes for more than 900 NIEHS postdoctoral fellows over the past 15 years. Postdoctoral fellows, or postdocs, are scientists who have received their doctoral degrees and are participating in a program that offers additional training.

Lead author and NIEHS computer scientist Hong Xu analyzed the data using the R Project for Statistical Computing, a free online program that displays data using graphs and charts. Shyamal Peddada, Ph.D., former NIEHS head of the Biostatistics and Computational Biology Branch, served as key advisor. The study appeared online in the journal Nature Biotechnology, and is the first standardized method for categorizing career outcomes of NIEHS postdocs.


NIEHS supports research to understand the effects of the environment on human health and is part of NIH. For more information on environmental health topics, visit Subscribe to one or more of the NIEHS news lists to stay current on NIEHS news, press releases, grant opportunities, training, events, and publications.


Xu H, Gilliam RST, Peddada SD, Buchold GM, Collins TRL. 2018. Visualizing detailed postdoctoral employment trends using a new career outcome taxonomy. Nat Biotechnol; doi: 10.1038/nbt.4059 [Online 15 January 2018].




Read Full Post »

17th Annual EmTech @ Media Lab, MIT – November 7 – 8, 2017, Cambridge, MA – This Year’s Themes, Speakers and Agenda

MIT Media Lab
Building E14
75 Amherst Street 
(Corner of Ames and Amherst)


  • Business Impact
  • Connectivity
  • Intelligent Machines
  • Rewriting Life
  • Sustainable Energy
  • Meet the Innovators Under 35

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston


will cover in REAL TIME

The 17th annual EmTech MIT – A Place of Inspiration, November 7 – 8, 2017, Cambridge, MA

MIT Technology Review’s EmTech conference

In attendance, covering LIVE using Social Media

Aviva Lev-Ari, PhD, RN







  • 8:00
    Registration & Breakfast
Opening Remarks – Elizabeth Bramson-Boudreau, MIT TR
  • In Media Lab – MIT and MIT Technology Review was established in 1899
  • EmTech 1999 – 100 years to MIT Technology Review
  • Innovations and pushing the boundaries
  • AI – potential and limitations
  • Climate change requires new technologies
  • Brain Technologies: Biology Vision
  • Tomorrow: emerging technologies: Cybercrime, role of technology
  • Automation and future of work
  • Partners: GE, Lamburghini
  • Lemelson-MIT
  • MITTR – Whova on AppleStore
The State of AI – Andrew Ng, CS.AI, Stanford University – was 2008 Young Innovator,
Founder,; Adjunct Professor, Stanford University
  • Trends in AI – AI is the new Electricity
  • Deep Learning & Neural Networks (NN):
  1. Input a picture –>> output: Is it You?
  2. loan application outcome: will you repay (%)
  3. picture from car – Output GPS address –>> Supervised Learning
  4.  doing act in <1 sec of thinking
  5. training SMALL, Medium size very large NN
  6. Algorithm innovations:

Supervised Learning algorithm types:

  • Transfer Learning
  • Unsupervised learning
  • Reinforcement learning – hunger for data: i.e., robotic applications

Importance of Data accumulation for launch a Product –  Users — data growth

  • Shopping Mall + website is not equal an Internet company
  • Internet company:
  1. push data to CEOs
  2. A–B Testing
  3. Short cycle time
  4. Decisions made by PM and ERP

AI era

traditional company + NN not equal AI company

  • Strategic data acquisition
  • Unified data warehouse
  • Precision automation
  • ORGANIZATION CHART to interface in a matrix with AI Teams – hire Ai in the Business Units
  • Scarce talent of AI


  • Children MUST learn to code
  • Human-Computer communication will be by writing code
Meet the Innovators Under 35
  • Future of work
  • warranted reliant digital connectivity
Break & Networking
AI’s Next Leap Forward

Tomasso Poggio, MIT, CSAIL, BCS

  • Deep learning  – next step
  • Bet on Center Brain Mind Machines (CBMM)
  • Josh Tennenbaum at MIT
  • Autonomous Driving – Amnon Shaashua, MobilEye
  • 20 years @ MI AI: Dailmer and MIT — detection of pedestrans
  • Powerful computers and algorithms – Reinforcement Learning Networks (Brain Science), models of Vision and Deep Learning Networks – WHEN they work?
  • Building Jarvis – a buttler application in AI built by Marc Zukenberg
  • NeuroScience – MobilEye, AlphaGo
  • CBMM – NSF $50 Million in AI funding  – Science of Intelligence and Engineering of Intelligence
  • MIT & Harvard plus several organization
  • Business Partners: MS Soft, Google bought MobilEye,
  • Center for Visual Gaze – 200 msec of visual processing
  • ERGO SUM: toward symbols, Cognitive core, visual system, Brain OS – running routines
  • Breakthroughs: Theory: under which conditions,
  1. Learning theory
  2. optimization Approximation Theory: Deep vs Shallow networks
  3. Intelligence is greatest problem to solve it is like LIFE, Tomasso Poggio, MIT, CSAIL, BCS
  4. machine can help human to think better, long time horizon is needed,

Kris Hammond, Prof. Northtwestern University

  • Data analytics and Ideas
  • words vs language – past, present, future – uniquely HUMAN, now machine language is Human Partner
  • language vs Ideas
  • machines knows a lot
  • facts, dat move to narrative
  • Language is understanding
  • FIN information: Decisions about allocations,
  • Turbidity data on the beach in Chicago: Which Beach is the cleanest vs the dirtiest
  • NARRATIVE ANALYTICS: data that machine can tell us what it has as a story and presented as intelligent language,

    Cognitive Science application to autonomous driving – Yibio Zhau, Tennenbaum Lab @MIT, ISEE.AI, Computer vision, Cognitive Science

  •  interpulate and extrapulate data needed for autonomous driving
  • reasoning beyond the system: Human intelligence , intentional reasoning, pattern recognition,
  • Ali baba – funding building of a Robot for autonomous driving – understanding by imagining – causes for behavior by others
  • ISEE – Next generation of AI — driving drivessless ly for thousands of miles
  • Car to car communication is a sensoring issue, negotiation need to be taught to machines

Young Scientists 35 years old or less

Austin Olson, Luminar – object detection 99% accuracy,

Angella Schoellig — Roborts, Prof. University of Toronto, robots in predictable environments

Lorenz Meier — Vertical Technologies – Drones and safety – DB of flights

Lunch & Networking
Adapting to the reality of climate change

Lee Krevat, Sempra –

owns Wind Farms- managing a Grid with renewable energy. Variable – Wind technology wind is variable – if wind blows too much switch to diesel. 100% renewable for one hour on Islands

Growth area:
  1. 20 cents diesel, wind is 10 cents help the enviroment

mainland, not yet used, price diesel vs wind

Solar wind generation – next biggest Technology in Energy


Alex Tepper,Avetars

Robotics, Drones, AI and the Future of Energy – A start up incubator sponsored and funded by GE
  • RAIL – Predict derailments
  • OIL & GAS – corrosion is the enemy — knowledge of corosion progression – using AI algorithms

Growth area: Aviation

John Holdren – Harvard University – Government  Role in ENERGY and Climate Change – Obama’s advisor Presidential CSO on Climate and energy

  • mitigation
  • adaptation
  • suffering – shortcomings of mitigation and adaptation
  • harm of business as usual
  • Efficiency standards during Obama Administration, assistance to other countries led to the Agreement in Paris 195 countirs — agreement to reduce emission. China and US declare cooperation on emission of gases into the environment.
  • All executive orders by Obama – were reverted by Trump
  • Innovations: Electricity from Solar increase and wind as well and batteries
  • Carbon capture and storage – technological challenge
  • Biofuel processing, liquid bio fuel
  • Nuclear innovations to nuclear waste
  • 2100 – 5% on defense and 2% on the environment – model under estimate the contribution of innovations for the long run.
  • 1000 businesses in deployment of technologies

Evelyn wang, MIT – Material Science – Sustainable energy – nano

  • material properties: superior properties of LOW DENSITIES
  • Light manipulation
  • membrane
  • CO2 capture
  • Technologies: Nnao, Thermoelectronics, energy and water
  • Solar 6% and wind 21%, biomass 5%voltaic
  • SOlar eneconversion
  • Nanophotonics: Solar energy conversion: photo
  • Nano absorber – area ratio; Emitter: silicon and silicon  – spectral approach
  • potential STPVs
  • Transportation using energy with emission
  • Power consumed by HVAC
  • Thermal Battery for Electric Vehicle: Adsorption Heating and Cooling
  • Desorption vs Adsoption: cooling vs Heating mode
  • High capacity adsobents – Zeolite  MOF enhancing capacity heat and mass transport
  • Tmal Battery Prototype: Hybrid, electric, stationary domestic HVAC.
  • Water harvesting from Air – metal organic Frameworks: Adsorption – harvest water without need of additional electricity
  • Opportunities for Advanced Materials

Prof. David Keith, Harvard University

  • technologies to stop global changing
  • research program
  • stratospheric aerosol cool planet – pollution masking global warming
  • solar geo-engineering, vs emission cut 3x BAU vs business as usual
  • Annual maximal Temperatures, extreme precipitation,
  • carbon emission worm up vs climate risk in Time
  •  use of technology for climate change mitigation: carbon removal
  • Solar engineering is the solution
Break & Networking
Meet the Innovators Under 35

Next Generation Brain Interfaces

Andrew Schwartz, University of Pittsburg

  • Causality is obscure
Lemelson-MIT Prize Honors & Reception
Lemelson-MIT Prize Honors Feng Zhang, MIT with the Prize for contributions to CRISPR Applications as a therapeutics method in genomics


  • 8:00
    Registration & Breakfast
9:00 Elizabeth Branson
9AM – 9:30AM Robots and AI in Everyday Life

Daniela Rus, CSAIL, MIT – Robots: drones, 3D Printing

hosted by David Rotman, MIT TR

  • supply chain and transportation – city will benefit from a different business model
  • autonomous driving deployed in Singapore
  • all vehicles on wheels can be made autonomous
  • blind – camera on a belt assists in navigation
  • ML: Patterns and predictions
  • AI – reasoning
  • robots: motion
  • Machine read entire libraries
  • Radiology: Read by machines vs by Radiology: AI  + Human — 0.5% error
  • Rural area medicine
  • Machines – Better Lawyers: NLP – read precedents to cases, machines can’t write a briefing or defend a plaintif
  • Factory and Automation: Robots roles – enable mass OPTIMIZATION  not only mass production
  • Machines do not have common sense and do not have ability to reason
  • crunching data vs analysis
  • JOB Categories:Tasks vs Professions: Routine data processing and labor task — are ready for automation
  • NEW jobs: User experience designer, GPS enable taxi drivers to drive and drove pay scale down
  • GDP – decreased 1966 – 2016
  • KY school to train coal miners to do data processing to become CODERS
  • JFK – new machines brings man back to jos – new jobs
  • AI supports NEW jobs: CS/AI part of literacy
  • people and machines – in collaboration


  • Who to make the transition?
  • CODING is key – people must be active in keeping up and continue to train
  • make it easy to make machines, interactions Man-Machine easier,
  • YOU ARE WRONG SIGNAL IS recognized by EEG
  • AI and Future of Work Conference at MIT – anxiety related to job changing due to technology
  • Technology can’t solve all problems, Technology helps, Technology implications on Policy – technology as a unifier societal force not a dividers
  • Transportation as Utility

9:30 – 10:00 AI and the Future of Work

Iyad Rahwan, MIT Media Lab, Introduction by Elizabeth Woyke, TR

  • Physical Therapist — will not be replaced by computerisation
  • Probability of computerisation: Skilled cities are better at economics shocks
  • Adam Smith – simple operations
  • Differential Impact from Automation on Cities – the larger the city more resilient to automation
  • City size vs clusters of occupations — cluster grow with city size
  • Impact on Middle Class vs Lower and Upper: low paying jobs, middle and high
  • Skills in Occupations: mapping SkillScape correlations with Education
  • Skills in demand


  • Urbanization took place – 80% live in cities around the World
  • Outliers in CIties by size and Skills: Boulder, CO – small size very skilled labor, politics support start ups and high tech


10AM – 10:30AM

Meet the Innovators Under 35

  • Tracy Chou – ProjectInclude – diversity
  1. All about data


  • Olga Russakovsky – Princeton University – Computer vision
  • AI for education of under privileged high school
  1. IM-GENET – Data sets encode human biases
  2. AI is powered by Data
  3. AI learns societal  biases
  4. Researchers shape AI
  • 10:30

    Break & Networking

  • 11:00 – 11:30 What is Social Media Doing to Society?
 Yasmin Green, Jigsaw, Google
  • 300 million reach of Ads posted by Google in the Internet
  • Fake news
  • Network shape
  • Veracity and popularity personalized
Hosted by Martin Giles, TR
  • e 11:30 – 11:45 Meet the Innovators under 35
  • Phillipa Gill  – UMass CS – Project of Network measurement on censorship measurement platforms
  • Joshua Browder – DoNotPay

11:45 – 12:00 The Emerging Threat of Cybercriminal AI

Shuman Ghosemajumder, Shape Security

Hosted by Martin Gile

  • CyberCrime is evolving using AI – Imitation Game – Turing Test restricted Turing Tests
  • Computer vision, Solving CAPUTRE – Copletely Automated Turing  Tests
  • CAPTCHA by Google
  • Credential Stuffing Accounts Attacks – SONY was hacked and 93,000 Passwords stolen
  • Clip Farms at Google
  • BLACKFISH – identify Credential Stuffing Accounts Attacks, all invalid password are not valid to be used by cyber attackers again – that authentication is no longer valid
  • Multi Factors Authentications vs ease of use to Log In
  • Knowledge Basis – Probabilistic  SYmbols – BlackFISH – technological advantage – iPhone stores a math formulation of characteristics of the finger print not the image of the fingure
  •  12:00
    Lunch & Networking – Lamborghini -super sport car
1:30 – 2PM
Technology Spotlight: Mind-Controlled VR
Ramses Alcaide, Neurable
Hosted by Rachel Metz, TR
  • Killer Platforme ==>Killer Interaction ==>Killer application
  • Reactive ==> Proactive
  • Brain Computer Interaction (BCI) – maximum Privacy no voice involved like in SPeech
  • Voice, Motion Tracking, eye tracking
  • Human intentionality – a World without limitations
  • NASA is a client
  • consol technology for navigation, typing,
  • Problems: Add to glasses or as an Ear piece
  • the signal is ACTION POTENTIAL
  • latency differences between individuals
  • Non-invasive to invasive to capture signals


2:00 – 2:30 Capturing Our Imagination:: Evolution of Brain-Machine Interfaces
Mary Lou Jepsen, Openwater
Hosted by Antonio Ragalado, TR
  • Using functional MRI technology for a NEW device to scan emotions rather than medical diseases
  • HOLOGRAPHY of the Brain – liquid crystal display is like transistors on a chip
  • OPTICS – DISCONTINUITY of Moore’s law – high resolution like functional MRI
  • Holographic LCD – scattering material VOXEL detector – measure intensity of light, no resolution, consumer camera speed OK Inexpensive
  • Human body scattering
  • HAT and Bandage
2:30 – 3PM Future of Work – REWARD DISOBEDIENCE –
New Prize of $250,000  – Ethics and governance in AI at MIT Media lab
Reid Hoffman, Greylock Partners Founder LinkedIn
conversation with Joi Ito, MIT Media Lab
  • Tell the Truth
  • Media Lab — a Non-disciplinary place
  • Universities play a role in Social Justice
  • FEAR of AI:
  1. For profit will own it all
  2. stupid AI will govern
  3. displace work
  4. espionage
  5. catalytic institute that will make a contribution to OPENNESS vs technological dominance

Joi Ito, MIT Media Lab: AI problems –

  • MUST be democratized – Now it is in the hands of very FEW
  • RISK SCORES can’t be contested in court because they are IP of for profit companies
  • Joi Ito, MIT Media Lab at MIT do good to Society vs make the most of money which the majority are doing
  • AUTONOMICH vs autonomous agents, said Joi Ito, MIT Media Lab – Hoffman: Design goals more symbiotic: Scaling, more productive, Season 2 launched today
  • Design principle – LEARNING vs EDUCATION, Joi Ito, MIT Media Lab

Hoffman on AI Technologies

  • shaping it to avoid catastrophic negatives
  • provide a public good via participation
Break & Networking
3:30 – 4 Big Problems, Big Data Solutions
Deb Roy, MIT media Lab
  • Tweets and News, Washington Post – Tracking tweets from US on Politics related to the Elections
  • National memory on Guns, Immigrations
  • Debate brief from tweets and News rooms
  • topic classifier,  Campaign finance, SHARE OF COVERAGE IN NEWS, SHARED OF VOICE ON TWITTER
  • deep neural network training algorithms
  • Passion Gap: cut data on Twitter – Trump supporters exhibited x2 fold energy vs the Democratic candidate
  • How does Media flow: Sanders, Clinton, Trump – each is a Media Source
  • Truth, Trust, Attention  – Fact checking
  • If Trust the source then I believe it is True
  • Public Opinion: The Politics of Resentment in Rural WI – Katherine Cramer
  • Listening Networks: Human- Human Interaction: Media sharing network – change week by week – the MOST innovative methodology developed to date for Public Opinion – presentation by
    Deb Roy, MIT media Lab  – using deep Neural network training
  1. main stream
  2. conservative
  3. liberal activist
  • Health Indicators:
  • Shared attention
  • Shared Reality
  • Varied Perspective – surface under-heard voices
3:30 – 4
Meet the Innovators Under 35
1. Svenja Hinderer, Germany
  • Valve – development of Tissues, biochemical properties
  • signaling molecules
  • mechanical strength – physiological
  • Attrach stem cells – proper matrix formation
  • Functional implants
2. Viktor Adalsteinsson
  • Cancer Precision medicine – Liquid biopsy – tumor mutations
  • entire Cancer Genome – from blood biopsy
  • Scaling: Broad Institute 100 collaborators – 3,000 blood sample genomical analysis
2.Tallis Gomes, CEO Entrepreneur, Brazil
  • Easy Taxi
  • Fighting inequality
  • 15Billion – Beauty Market
3. Abidigani Diriye
  • IBM Research Africa – 300 million adults – lack of access to financial services
  • Univesities, Government  – start ups to scale ideas
Eyad Janneh
  • 5:00
    2017 Innovator Under 35 Awards & Reception
  1. Speakers
    • Viktor

      Group Leader, Broad Institute of MIT and Harvard

      2017 Innovator Under 35


    CEO, Sila Nano

    2017 Innovator Under 35

    • rechargeable battery
    • new class of materials charge and discharge in battery
    • store more energy
    • more better designed electronics: electrified flight, solar, car: Hybrid and electric
    • 21st Century belongs to electrification vs combustion in the 20th century,


      CEO, Sila Nano

    • Tracy

      Founding Advisor, Project Include

      2017 Innovator Under 35

    • Adrienne

      Software Engineer, Google

      2017 Innovator Under 35

    • Phillipa

      Assistant Professor, University of Massachusetts, Amherst

      2017 Innovator Under 35

    • Tallis

      CEO, Singu

      2017 Innovator Under 35


    CEO, WafaGames

    2017 Innovator Under 35

    • Ian

      Staff Research Scientist, Google Brain, development occurred at OpenAI

      GAN’s – Generative Adversarial Network – from AI Optimization to Game Theory

      2017 Innovator Under 35

    • Yasmin

      Director of Research and Development, Jigsaw at Google

      Addressing Online Threats to Global Security

    • Kris

      Chief Scientist and Cofounder, Narrative Science

      AI’s Language Problem

    • Svenja

      Scientist, Fraunhofer IGB

      2017 Innovator Under 35

    • Reid

      Cofounder, LinkedIn; Partner, Greylock Partners

      The Future of Work

    • John

      Professor, Harvard University

      Climate Disruption: Technical Approaches to Mitigation and Adaptation

    • Joi

      Director, MIT Media Lab

      The Future of Work

    • Mary Lou

      Founder, Openwater

      Capturing Our Imagination: The Evolution of Brain-Machine Interfaces

    • David

      Professor, Harvard University; Founder, Carbon Engineering

      The Growing Case for Geoengineering

    • Neha

      Cofounder and CTO, Confluent

      2017 Innovator Under 35

    • Andrew

      Founder,; Adjunct Professor, Stanford University

      The State of AI

    • Tomaso

      Investigator, McGovern Institute; Eugene McDermott Professor, Brain and Cognitive Sciences, MIT

      Understanding Intelligence

    • Olga

      Assistant Professor, Princeton University

      2017 Innovator Under 35


    Marie Curie Fellow, EPFL

    2017 Innovator Under 35

    • disruptive technology in the energy space
    • Gang

      Chief Scientist, Alibaba

      2017 Innovator Under 35

    • Jianxiong

      Chief Executive Officer, AutoX, Inc.

      2017 Innovator Under 35

      CAMERA-first solution affordable self-driving

Read Full Post »

Lectures by The 2017 Award Recipients of Warren Alpert Foundation Prize in Cancer Immunology, October 5, 2017, HMS, 77 Louis Paster, Boston

Top, from left: James Allison and Lieping Chen. Bottom, from left: Gordon Freeman, Tasuku Honjo (NOT ATTENDED), Arlene Sharpe.

Aviva Lev-Ari, PhD, RN was in attendance and covered this event LIVE


The 2017 Warren Alpert Foundation Prize has been awarded to five scientists for transformative discoveries in the field of cancer immunology.

Collectively, their work has elucidated foundational mechanisms in cancer’s ability to evade immune recognition and, in doing so, has profoundly altered the understanding of disease development and treatment. Their discoveries have led to the development of effective immune therapies for several types of cancer.

The 2017 award recipients are:

  • James Allison, professor of immunology and chair of the Department of Immunology, The University of Texas MD Anderson Cancer Center – Immune checkpoint blockage in Cancer Therapystrictly Genomics based drug
  1. 2017 FDA approved a gemonics based drug
  2. and co-stimulatory signals
  3. CTLA-4 blockade, CD28, AntiCTLA-4 induceses regression of Transplantable Murine tumo
  4. enhance tumor-specific immune response
  5. Fully antibody human immune response in 10,000 patients – FDA approved 2011
  6. Metastatic melanoma – 3 years survival, programmed tumor death, PD-1, MHC-A1
  7. Ipi/Nivo vs. Ipi – combination – 60% survival vs Ipi alone
  8. Anti CTA4 va Anti-PD-1
  9. responsive T cell population – MC38 TILs
  10. MC38 Infiltrating T cell populations: Treg, CD4, Effector, CD8, NKT/gamma-delta
  11. Checkpoint blockage modulates infiltrating T cell population frequencies
  12. T reg correlated with Tumor growth
  13. Combination therapy lead to CURE survival at 80% rate vs CTAL-4 40% positive outcome

Not Attended — Tasuku Honjo, professor of immunology and genomic medicine, Kyoto University – Immune regulation of Cancer Therapy by PD-1 Blockade


  • Lieping Chen, United Technologies Corporation Professor in Cancer Research and Professor of immunobiology, of dermatology and of medicine, Yale University – Adoptive Resistance: Molecular Pathway t Cancer Therapy – focus on solid tumors
  1. Enhancement – Enhance normal immune system – Co-stimulation/Co-inhibition Treg, and Cytokines, adoptive cell therapy, Lymphoid organs stores
  2. Normalization – to correct defective immune system – normalizing tumor immunity, diverse tumor escape mechanisms
  3. Anti-PD therapy: regression of large solid tumors: normalizing tumor immunity targeting tumor microenvironment: Heterogeneity, functional modulation, cellular and molecular components – classification by LACK of inflamation, adaptive resistance, other inhibitory pathways, intrinsic induction
  4. avoid autoimmune toxicity,
  5. Resetting immune response (melanoma)
  6. Understad Resistance: Target missing resistance or Adaptive resistance Type II= acquired immunity
  • Gordon Freeman, professor of medicine, Dana-Farber Cancer Institute, Harvard Medical School – PD-L1/PD-1 Cancer Immunotherapy
  1. B7 antibody
  2. block pathway – checkpoint blockage, Expand the T cells after recognition of the disease. T cell receptor signal, activation, co -stimulatory: B71 molecule, B72 – survival signals and cytokine production,.Increased T cell proliferation,
  3. PDL-1 is a ligand of PD 1. How T cell die? genes – PD1 Gene was highly expressed,
  4. Interferon gamma upregulate PD-L1 expression
  5. Feedback loop Tumor – stimulating immune response, interferon turn off PD1
  6. PD-L1 and PD-L2 Expression: Interferom
  7. Trancefuctor MHC, B7-2
  8. PD-L! sisgnat inhibit T-cell activation: turn off Proliferation and cytokine production — Decreasing the immune response
  9. T cell DNA Content: No S-phase devided cell
  10. PD-L1 engagement of PD-1 results in activation : Pd-1 Pathway inhibits T Cell Actiivation – lyposite motility,
  11. Pd-L2 is a second ligand for PD-1 and inhibits T cell activation
  12. PDl-1 expression: BR CA, Ovarian, Colonol-rectal, tymus, endothelial
  13. Blockage of the Pathway – Immune response enhanced
  14. Dendritic cells express PD-L1, PD-L2 and combination of Two, Combination was best of all by increase of cytokine production, increasing the immune response.
  15. PD-L1 blockade enhanced the immune response , increase killing and increased production of cytokines,
  16. anti-tumor efficacy of anti-PD-1/Pd-L1
  17. Pancreatic and colono-rector — PD-L, PDL1, PDL2 — does not owrkd.
  18. In menaloma: PD-1 works better than CYLA-4
  19. Comparison of Targeted Therapy: BRAF TKI vs Chemo high % but short term
  20. Immunotherapy – applies several mechanism: pre-existing anti-therapy
  21. Immune desert: PD=L does not work for them
  23. PD blockage + nutrients and probiotic
  24. Tumor Genome Therapy
  25. Tumore Immuno-evasion Score
  26. Antigens for immune response – choose the ones
  27. 20PD-1 or PD-L1 drugs in development


  • Arlene Sharpe, the George Fabyan Professor of Comparative Pathology, Harvard Medical School; senior scientist, department of pathology, Brigham and Women’s Hospital – Multi-faceted Functionsof the PD-1 Pathway
  1. function of the pathway: control T cell activation and function of maintain immune tolerance
  2. protect tissues from damage by immune response
  3. T cell dysfunction during cancer anf viral infection
  4. protection from autoimmunity, inflammation,
  5. Mechanism by which PD-1 pathway inhibits anti-tumor immunity
  6. regulation of memoryT cell responce of PD-1
  7. PD-1 signaling inhibit anti-tumor immunity
  8. Compare: Mice lacking CD8-Cre- (0/5) cleared vs PD-1-/-5/5 – PD-1 DELETION: PARTIAL AND TIMED: DELETION OF PD-1 ON HALF OG TILS STARTING AT DAY 7 POSTTUMOR IMPLANTATION OF BOTH PD-1 AND PD-1 TILS: – Tamoxifen days 7-11
  9. Transcription profile: analysis of CD8+ TILs reveal altered metabolism: Fatty Acid Metabolism vs Oxidative Phosphorylation
  10. DOes metabolic shift: WIld type mouth vs PD-1-/_ P14: analyze Tumor cell killingPD-1-/- enhanced FAO increases CD8+ T cell tocicity
  11. Summary: T cell memory development and PD-1: T effectors vs T cell memory: Primary vs Secondary infection: In the absent of PD-1, CD8+ T cels show increase expansion of T cells
  12. INFLUENZA INFECTION: PRIMARY more virus in lung in PD-1 is lacking
  13. Acute infection: PD-1 controls memory T cell differentiation vs PD-1 increase expansion during effector phase BUT impaired persistence during memory phase: impaired cytokine production post re-challenge
  14. PD-1 immunotherapy work for patients with tumor: Recall Response and Primary response
  15. TIL density Primary vs Long term survivor – 5 days post tumor implantation – rechallenged long term survival
  16. Hot tumor vs Cold tumor – Deletion of PD-1 impairs T memory cell development


Opening Remarks: George Q. Daley, MD, PhD, DEAN, HMS

  • Scientific collaboration check point – avoid the body attacking itself, sabotaging the immune system
  • 1987 – Vaccine for HepB
  • Eight of the awardees got the Nobel Prize


Moderated by Joan Brugge, PhD, HMS, Prof. of Cell Biology

  • Evolution of concepts of Immunotherapy: William Coley’s Toxin streptoccocus skin infection.
  • 20th century: Immuno-surveilence, Immune response – field was dead in 1978 replaced by Immunotherapy
  • Rosenberg at NIH, high dose of costimulatory molecule prevented tumor reappearanceantbody induce tumor immunity–>> immune theraphy by check point receptor blockade – incidence of tumor in immune compromised mice – transfer T cell
  • T cell defficient, not completely defficient, self recognition of tumor,
  • suppress immmune – immune evasion
  • Michael Atkins, MD, Detupy Director, Georgetown-Lombardi, Comprehensive Cancer Center Clinical applications of Checkpoint inhibitors: Progress and Promise
  1. Overwhelm the Immune system, hide, subvert, Shield, defend-deactivating tumor trgeting T cells that ATTACK the immune system
  2. Immune system to TREAT the cancer
  3. Monotherapy – anti PD1/PD-L1: Antagonist activity
  4. Evading immune response: prostate, colcn
  5. MMR deficiency
  6. Nivolumab in relaped/Refractory HODGKIN LYMPHOMAS – over expression of PD-L1 and PDL2in Lymphomas
  7. 18 month survival better with Duv in Lung cancer stage 3 – anti PD-1- adjuvant therapy with broad effectiveness
  8. Biomarkers for pD-L1 Blockage
  9. ORR higher in PD-L1
  10. Improve Biomarkers: Clonality of T cells in Tumors
  11. T-effector Myeloid Inflammation Low – vs Hogh:
  12. Biomarker Model: Neoantigen burden vs Gene expression vs CD8+
  13. Tissue DIagnostic Labs: Tumor microenveironmenr
  14. Microbiome
  15. Combination: Nivo vs Nivo+Ipi is superior: DETERMINE WHEN TO STOP TREATMENT
  16. 15/16 stopped treatment – Treatment FREE SURVIVAL
  17. Sequencing with Standard Therapies
  18. Brain metastasis – Immune Oncology Therapy – crosses the BBB
  19. Less Toxic regimen, better toxicity management,
  20. Use Immuno therapy TFS
  21. combination – survival must be justified
  22. Goal: to make Cancer a curable disease vs cancer becoming a CHronic disease


Closing Remarks: George Q. Daley, MD, PhD, DEAN, HMS


The honorees will share a $500,000 prize and will be recognized at a day-long symposium on Oct. 5 at Harvard Medical School.

The Warren Alpert Foundation, in association with Harvard Medical School, honors trailblazing scientists whose work has led to the understanding, prevention, treatment or cure of human disease. The award recognizes seminal discoveries that hold the promise to change our understanding of disease or our ability to treat it.

“The discoveries honored by the Warren Alpert Foundation over the years are remarkable in their scope and potential,” said George Q. Daley, dean of Harvard Medical School. “The work of this year’s recipients is nothing short of breathtaking in its profound impact on medicine. These discoveries have reshaped our understanding of the body’s response to cancer and propelled our ability to treat several forms of this recalcitrant disease.”

The Warren Alpert Foundation Prize is given internationally. To date, the foundation has awarded nearly $4 million to 59 scientists. Since the award’s inception, eight honorees have also received a Nobel Prize.

“We commend these five scientists. Allison, Chen, Freeman, Honjoand Sharpe are indisputable standouts in the field of cancer immunology,” said Bevin Kaplan, director of the Warren Alpert Foundation. “Collectively, they are helping to turn the tide in the global fight against cancer. We couldn’t honor more worthy recipients for the Warren Alpert Foundation Prize.”

The 2017 award: Unraveling the mysterious interplay between cancer and immunity

Understanding how tumor cells sabotage the body’s immune defenses stems from the collective work of many scientists over many years and across multiple institutions.

Each of the five honorees identified key pieces of the puzzle.

The notion that cancer and immunity are closely connected and that a person’s immune defenses can be turned against cancer is at least a century old. However, the definitive proof and demonstration of the steps in this process were outlined through findings made by the five 2017 Warren Alpert prize recipients.

Under normal conditions, so-called checkpoint inhibitor molecules rein in the immune system to ensure that it does not attack the body’s own cells, tissues and organs. Building on each other’s work, the five award recipients demonstrated how this normal self-defense mechanism can be hijacked by tumors as a way to evade immune surveillance and dodge an attack. Subverting this mechanism allows cancer cells to survive and thrive.

A foundational discovery made in the 1980s elucidated the role of a molecule on the surface of T cells, the body’s elite assassins trained to seek, spot and destroy invaders.

A protein called CTLA-4 emerged as a key regulator of T cell behavior—one that signals to T cells the need to retreat from an attack. Experiments in mice lacking CTLA-4 and use of CTLA-4 antibodies demonstrated that absence of CTLA-4 or blocking its activity could lead to T cell activation and tumor destruction.

Subsequent work identified a different protein on the surface of T cells—PD-1—as another key regulator of T cell response. Mice lacking this protein developed an autoimmune disease as a result of aberrant T cell activity and over-inflammation.

Later on, scientists identified a molecule, B7-H1, subsequently renamed PD-L1, which binds to PD-1, clicking like a key in a lock. This was followed by the discovery of a second partner for PD-1—the molecule PD-L2—which also appeared to tame T-cell activity by binding to PD-1.

The identification of these molecules led to a set of studies showing that their presence on human and mouse tumors rendered the tumors resistant to immune eradication.

A series of experiments further elucidated just how tumors exploit the interaction between PD-1 and PD-L1 to survive. Specifically, some tumor cells appeared to express PD-L1, essentially “wrapping” themselves in it to avoid immune recognition and destruction.

Additional work demonstrated that using antibodies to block this interaction disarmed the tumors, rendering them vulnerable to immune destruction.

Collectively, the five scientists’ findings laid the foundation for antibody-based therapies that modulate the function of these molecules as a way to unleash the immune system against cancer cells.

Antibody therapy that targets CTLA-4 is currently approved by the FDA for the treatment of melanoma. PD-1/PD-L1 inhibitors have already shown efficacy in a broad range of cancers and have been approved by the FDA for the treatment of melanoma; kidney; lung; head and neck cancer; bladder cancer; some forms of colorectal cancer; Hodgkin lymphoma and Merkel cell carcinoma.

In their own words

“I am humbled to be included among the illustrious scientists who have been honored by the Warren Alpert Foundation for their contributions to the treatment and cure of human disease in its 30+ year history.  It is also recognition of the many investigators who have labored for decades to realize the promise of the immune system in treating cancer.”
        -James Allison

“The award is a great honor and a wonderful recognition of our work.”
         Lieping Chen

I am thrilled to have made a difference in the lives of cancer patients and to be recognized by fellow scientists for my part in the discovery of the PD-1/PD-L1 and PD-L2 pathway and its role in tumor immune evasion.  I am deeply honored to be a recipient of the Alpert Award and to be recognized for my part in the work that has led to effective cancer immunotherapy. The success of immunotherapy has unleashed the energies of a multitude of scientists to further advance this novel strategy.”
                                        -Gordon Freeman

I am extremely honored to receive the Warren Alpert Foundation Prize. I am very happy that our discovery of PD-1 in 1992 and subsequent 10-year basic research on PD-1 led to its clinical application as a novel cancer immunotherapy. I hope this development will encourage many scientists working in the basic biomedical field.”
-Tasuku Honjo

“I am truly honored to be a recipient of the Alpert Award. It is especially meaningful to be recognized by my colleagues for discoveries that helped define the biology of the CTLA-4 and PD-1 pathways. The clinical translation of our fundamental understanding of these pathways illustrates the value of basic science research, and I hope this inspires other scientists.”
-Arlene Sharpe

Previous winners

Last year’s award went to five scientists who were instrumental in the discovery and development of the CRISPR bacterial defense mechanism as a tool for gene editing. They were RodolpheBarrangou of North Carolina State University, Philippe Horvath of DuPont in Dangé-Saint-Romain, France, Jennifer Doudna of the University of California, Berkeley, Emmanuelle Charpentier of the Max Planck Institute for Infection Biology in Berlin and Umeå University in Sweden, and Virginijus Siksnys of the Institute of Biotechnology at Vilnius University in Lithuania.

Other past recipients include:

  • Tu Youyou of the China Academy of Chinese Medical Science, who went on to receive the 2015 Nobel Prize in Physiology or Medicine with two others, and Ruth and Victor Nussenzweig, of NYU Langone Medical Center, for their pioneering discoveries in chemistry and parasitology of malaria and the translation of their work into the development of drug therapies and an anti-malarial vaccine.
  • Oleh Hornykiewicz of the Medical University of Vienna and the University of Toronto; Roger Nicoll of the University of California, San Francisco; and Solomon Snyder of the Johns Hopkins University School of Medicine for research into neurotransmission and neurodegeneration.
  • David Botstein of Princeton University and Ronald Davis and David Hogness of Stanford University School of Medicine for contributions to the concepts and methods of creating a human genetic map.
  • Alain Carpentier of Hôpital Européen Georges-Pompidou in Paris and Robert Langer of MIT for innovations in bioengineering.
  • Harald zur Hausen and Lutz Gissmann of the German Cancer Research Center in Heidelberg for work on the human papillomavirus (HPV) and cancer of the cervix. Zur Hausenand others were honored with the Nobel Prize in Physiology or Medicine in 2008.

The Warren Alpert Foundation

Each year the Warren Alpert Foundation receives between 30 and 50 nominations from scientific leaders worldwide. Prize recipients are selected by the foundation’s scientific advisory board, which is composed of distinguished biomedical scientists and chaired by the dean of Harvard Medical School.

Warren Alpert (1920-2007), a native of Chelsea, Mass., established the prize in 1987 after reading about the development of a vaccine for hepatitis B. Alpert decided on the spot that he would like to reward such breakthroughs, so he picked up the phone and told the vaccine’s creator, Kenneth Murray of the University of Edinburgh, that he had won a prize. Alpert then set about creating the foundation.

To award subsequent prizes, Alpert asked Daniel Tosteson (1925-2009), then dean of Harvard Medical School, to convene a panel of experts to identify scientists from around the world whose research has had a direct impact on the treatment of disease.


Read Full Post »

Cleveland Clinic: Change at the Top,  Tomislay “Tom” Mihaljevic, M.D., as its next CEO and President to succeed Toby Cosgrove, M.D., effective Jan. 1, 2018

Reporter: Aviva Lev-Ari, PhD, RN


Cleveland Clinic’s Board of Governors and Board of Directors unanimously selected Dr. Mihaljevic based on the unanimous recommendation of a nomination committee chaired by Mr. Rich that conducted an extensive review of potential successors. Drs. Cosgrove and Mihaljevic will work on a transition process together through the end of the year. As of Jan. 1, 2018, Dr. Mihaljevic will assume the full duties of president and CEO, while Dr. Cosgrove will move to an advisory role to be determined by the Board of Directors and Dr. Mihaljevic.

A native of Croatia and a naturalized American citizen, Dr. Mihaljevic earned his medical degree from the University of Zagreb, before moving to the United States in 1995 to join Brigham and Women’s Hospital in Boston. He moved to Cleveland Clinic in 2004 as a cardiothoracic surgeon specializing in minimally invasive and robotically assisted cardiac surgeries – particularly robotic mitral valve repair – complex valve operations and reoperations, heart failure surgery, and heart transplantation. He helped to build Cleveland Clinic into the world’s largest robotic practice.

Dr. Mihaljevic has been on the editorial review board for prestigious medical journals. He is the author or co-author of more than 145 articles in medical and peer-reviewed scientific journals, and is the author of a numerous textbook chapters on robotic and minimally invasive mitral valve surgery, and heart valve disease. In 2005, Dr. Mihaljevic received a patent for a novel cardioscopy system for minimally invasive cardiac surgery. He earned the Cleveland Clinic Innovation Award in both 2006 and 2007.

Dr. Mihaljevic, 53, joined Cleveland Clinic in 2004 as a cardiothoracic surgeon specializing in minimally invasive and robotically assisted cardiac surgeries. Since 2015, Dr. Mihaljevic has served as CEO of Cleveland Clinic Abu Dhabi, overseeing the hospital’s strategy and operations as the first US multispecialty hospital to be replicated outside of North America, including directly managing the hospital’s Patient Experience and Strategy & Business Development programs.

Tomislav Mihaljevic, M.D. 

“Dr. Mihaljevic brings a depth of experience, first as an innovative, world-class surgeon and more recently as a hospital executive focused on healthcare quality and safety, patient experience and business strategy,” said Robert E. Rich Jr., chair of Cleveland Clinic’s Board of Directors. “By nearly every measure – quality, accessibility, finances, innovation, reputation – Cleveland Clinic has made unprecedented strides since Dr. Cosgrove became CEO and president in 2004. Following in his footsteps would be challenging for anybody, but Dr. Mihaljevic has the background, skills and vision to move Cleveland Clinic forward to even greater heights.”



Other related articles published in this Open Access Online Scientific Journal, include the following:


Articles on Minimally Invasive Surgery (MIS)

Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions

Author, Introduction and Summary: Justin D Pearlman, MD, PhD, FACC, and Article Curator: Aviva Lev-Ari, PhD, RN


Less is More: Minimalist Mitral Valve Repair: Expert Opinion of Prem S. Shekar, MD, Chief, Division of Cardiac Surgery, BWH – #7, 2017 Disruptive Dozen at #WMIF17

Reporter: Aviva Lev-Ari, PhD, RN


Left Main Coronary Artery Disease (LMCAD): Stents vs CABG – The less-invasive option is Equally Safe and Effective

Reporter: Aviva Lev-Ari, PhD, RN


New method for performing Aortic Valve Replacement: Transmural catheter procedure developed at NIH, Minimally-invasive tissue-crossing – Transcaval access, abdominal aorta and the inferior vena cava

Reporter: Aviva Lev-Ari, PhD, RN


Minimally Invasive Valve Therapy Programs: Recommendations by SCAI, AATS, ACC, STS

Reporter: Aviva Lev-Ari, PhD, RN


Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure?

Author, and Content Consultant to e-SERIES A: Cardiovascular Diseases: Justin Pearlman, MD, PhD, FACC and Article Curator: Aviva Lev-Ari, PhD, RN


Call for the abandonment of the Off-pump CABG surgery (OPCAB) in the On-pump / Off-pump Debate, +100 Research Studies

Curator: Aviva Lev-Ari, PhD, RN


3D Cardiovascular Theater – Hybrid Cath Lab/OR Suite, Hybrid Surgery, Complications Post PCI and Repeat Sternotomy

Curator: Aviva Lev-Ari, PhD, RN


Vascular Surgery: International, Multispecialty Position Statement on Carotid Stenting, 2013 and Contributions of a Vascular Surgeonat Peak Career – Richard Paul Cambria, MD

Author and Curator: Aviva Lev-Ari, PhD, RN


Becoming a Cardiothoracic Surgeon: An Emerging Profile in the Surgery Theater and through Scientific Publications 

Author and Curator: Aviva Lev-Ari, PhD, RN


Carotid Endarterectomy (CEA) vs. Carotid Artery Stenting (CAS): Comparison of CMMS high-risk criteria on the Outcomes after Surgery:  Analysis of the Society for Vascular Surgery (SVS) Vascular Registry Data

Writer and Caurator: Larry H. Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN


Open Abdominal Aortic Aneurysm (AAA) repair (OAR) vs. Endovascular AAA Repair (EVAR) in Chronic Kidney Disease (CKD) Patients –  Comparison of Surgery Outcomes

Writer and Curator: Larry H. Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN



Read Full Post »

Emerging STAR in Molecular Biology, Synthetic Virology and Genomics: Clodagh C. O’Shea: ChromEMT – Visualizing 3D chromatin structure


Curator: Aviva Lev-Ari, PhD, RN


On 8/28/2017, I attend and covered in REAL TIME the CHI’s 5th Immune Oncology Summit – Oncolytic Virus Immunotherapy, August 28-29, 2017 Sheraton Boston Hotel | Boston, MA


I covered in REAL TIME this event and Clodagh C. O’Shea talk at the conference.

On that evening, I e-mailed my team that

“I believe that Clodagh C. O’Shea will get the Nobel Prizebefore CRISPR


11:00 Synthetic Virology: Modular Assembly of Designer Viruses for Cancer Therapy


Clodagh O’Shea, Ph.D., Howard Hughes Medical Institute Faculty Scholar; Associate Professor, William Scandling Developmental Chair, Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies

Design is the ultimate test of understanding. For oncolytic therapies to achieve their potential, we need a deep mechanistic understanding of virus and tumor biology together with the ability to confer new properties.

To achieve this, we have developed

  • combinatorial modular genome assembly (ADsembly) platforms,
  • orthogonal capsid functionalization technologies (RapAd) and
  • replication assays that have enabled the rational design, directed evolution, systematic assembly and screening of powerful new vectors and oncolytic viruses.


Clodagh O’Shea’s Talk In Real Time:

  • Future Cancer therapies to be sophisticated as Cancer is
  • Targer suppresor pathways (Rb/p53)
  • OV are safe their efficacy ishas been limited
  • MOA: Specify Oncolytic Viral Replication in Tumor cells Attenuate – lack of potency
  • SOLUTIONS: Assembly: Assmble personalized V Tx fro libraries of functional parts
  • Adenovirus – natural & clinical advantages
  • Strategy: Technology for Assmbling Novel Adenovirus Genomes using Modular Genomic Parts
  • E1 module: Inactives Rb & p53
  • core module:
  • E3 Module Immune Evasion Tissue targeting
  • E4 Module Activates E2F (transcription factor TDP1/2), PI3K
  • Adenovirus promoters for Cellular viral replication — Tumor Selective Replication: Novel Viruses Selective Replicate in RB/p16
  • Engineering Viruses to overcome tumor heterogeneity
  • Target multiple & Specific Tumor Cel Receptors – RapAd Technology allows Re-targeting anti Rapamycin – induced targeting of adenovirus
  • Virus Genome: FKBP-fusion FRB-Fiber
  • Engineer Adenovirus Caspids that prevent Liver uptake and Sequestration – Natural Ad5 Therapies 
  • Solution: AdSyn335 Lead candidat AdSyn335 Viruses targeting multiple cells
  • Engineering Mutations that enhanced potency
  • Novel Vector: Homes and targets
  • Genetically engineered PDX1 – for Pancreatic Cancer Stroma: Early and Late Stage
On Twitter:

Engineer Adenovirus Caspids prevent Liver uptake and Sequestration – Natural Ad5 Therapies C. O’Shea, HHDI

Scientist’s Profile: Clodagh C. O’Shea


BS, Biochemistry and Microbiology, University College Cork, Ireland
PhD, Imperial College London/Imperial Cancer Research Fund, U.K.
Postdoctoral Fellow, UCSF Comprehensive Cancer Center, San Francisco, U.S.A


O’Shea Lab @Salk


  • 2016 Howard Hughes Medical Institute Faculty Scholar
  • 2014 W. M. Keck Medical Research Program Award
  • 2014 Rose Hills Fellow
  • 2011Science/NSF International Science & Visualization Challenge, People’s Choice
  • 2011 Anna Fuller Award for Cancer Research
  • 2010, 2011, 2012 Kavli Frontiers Fellow, National Academy of Sciences
  • 2009 Sontag Distinguished Scientist Award
  • 2009 American Cancer Society Research Scholar Award
  • 2008 ACGT Young Investigator Award for Cancer Gene Therapy
  • 2008 Arnold and Mabel Beckman Young Investigator Award
  • 2008 William Scandling Assistant Professor, Developmental Chair
  • 2007 Emerald Foundation Schola


Clodagh C. O’Shea: ChromEMT: Visualizing 3D chromatin structure and compaction in interphase and mitotic cells | Science


Clodagh C. O’Shea

In Press

Jul 27, 2017 – Salk scientists solve longstanding biological mystery of DNA organization

Sep 22, 2016 – Clodagh O’Shea named HHMI Faculty Scholar for groundbreaking work in designing synthetic viruses to destroy cancer

Oct 05, 2015 – Clodagh O’Shea awarded $3 million to unlock the “black box” of the nucleus

Aug 27, 2015 – The DNA damage response goes viral: a way in for new cancer treatments

Apr 12, 2013 – Salk Institute promotes three top scientists

Oct 16, 2012 – Cold viruses point the way to new cancer therapies

Aug 25, 2010 – Use the common cold virus to target and disrupt cancer cells?

Oct 22, 2009 – Salk scientist receives The Sontag Foundation’s Distinguished Scientist Award

May 15, 2008 – Salk scientist wins 2008 Beckman Young Investigator Award

Mar 24, 2008 – Salk scientist wins 2007 Young Investigator’s Award in Gene Therapy for Cancer

Read Full Post »

Shaun Coughlin from UCSF Cardiovascular Research Center to cardio group for the Novartis Institute for Biomedical Research in Cambridge, MA

Reporter: Aviva Lev-Ari, PhD, RN


The dean of the UCSF med school, Talmadge King, had this to say in his sendoff today:

Coughlin’s “research discoveries revealed a mechanism by which proteases regulate cellular behaviors including a key mechanism that controls blood platelet activation and clot formation. This work led to a new medical therapy for preventing heart attacks and strokes and has been honored by the American Heart Association’s Basic Science Award in 2003 and its Research Achievement Award in 2014. Among his numerous other awards are the Bristol-Myers Squibb Cardiovascular Research Award and the Distinguished Career Award from the International Society on Thrombosis and Haemostasis.”


Read Full Post »

@ –  A Case Study on the LEADER in Curation of Scientific Findings

Author: Aviva Lev-Ari, PhD, RN


Multi-facets of the LPBI Group Intellectual Property (IP) ASSETS




  • Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP

  • Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Aviva Lev-Ari, PhD, RN


Innovations in e-Scientific Publishing Methodology Development accomplished by LPBI Group:

A.  Methodology for Curation of Scientific Findings – implementations for

  • Multi-Auhtors Authoring Cloud-based Platform


  • Journal Statistics – Interdisciplinary Journal covers interfaces of six domains (Life sciences, Pharmaceuticals, Medicine, Healthcare Policy, Biotech Intelligence and Medical Devices)

Curations of Scientific Findings of peer reviewed articles in top three journals in each of the Six domain

Curations written on a multi-Authoring platform by MDs, MD/PhDs, PharmD and PhDs, all 15 years after graduation of the advanced degree program, and each has a publication list before joined my team – they write clinical and medical interpretations of the scientific frontier as evidenced in the Scientific Finding section of published articles in Cell, Nature, Science, NEJM, other top journals in these six domains.

  1. Volume: 1.3 Million eReaders, ~5,150 Scientific articles, +500 categories of Research defining the Journal Ontology, 9,500 tags, 7,300, scientific comment on the articles submitted and exchange recorded between the Scientific community and our Team members
  2. Top two articles >25,000 eReaders
  3. Clicks on two Top Authors: >551,000
  4. from NIH +3,700 hits
  5. 2250 Journal subscribers by e-mail
  6. +6,200 Biotech Executive following up on LinkedIn
  • BioMed e-Series of e-Books in Medicine – 16 Volumes in Five e-Series: Cardiovascular, Genomics, Cancer, Immunology, Patient-centered Medicine

  • Team expertise
  1. e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point
  2. FIVE years of e-Scientific Publishing, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 4/27/2017
  3. Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

B.  Methodology for REAL TIME Coverage of Scientific Conferences using Social Media and Real Time e-Proceedings Generation: Conferences in Biotech, Life Sciences and Medicine

  • In House Developed Methodology for Real Time Press Coverage of Biotech Top International conferences – selective  topics covered at conferences lead to NEW Curations in the Journal


9 results for Kindle Store : “Aviva Lev-Ari”

Sort by 
Price: Low to High
Price: High to Low
Avg. Customer Review
Publication Date
Showing most relevant results. See all results for .
  • Product Details

    Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2)

    May 13, 2017 | Kindle eBook

    by Larry H. Bernstein and Demet Sag
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

    Nov 28, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Stephen J. Williams PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1)

    Jun 20, 2013 | Kindle eBook

    by Margaret Baker PhD and Tilda Barliya PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Genomics Orientations for Personalized Medicine (Frontiers in Genomics Research Book 1)

    Nov 22, 2015 | Kindle eBook

    by Sudipta Saha PhD and Marcus W Feldman PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1)

    Jul 21, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Prabodah Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3)

    Dec 26, 2015 | Kindle eBook

    by Larry H. Bernstein MD FACP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1)

    Aug 10, 2015 | Kindle eBook

    by Larry H Bernstein MD FCAP and Prabodh Kumar Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

    Dec 26, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Ritu Saxena PhD
    Subscribers read for free.
    Auto-delivered wirelessly
  • Product Details

    Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation

    Nov 29, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly

Read Full Post »

Older Posts »